Lung cancer
Conditions
Interventions
Bupivacaine Group:Ultrasound-guided injection of bupivacaine into the serratus anterior plane for regional blockade
Liposomal Bupivacaine Group:Ultrasound-guided injection of liposomal bupivacaine into the serratus plane for regional block
Sponsors
Quzhou People Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.The participant has been fully informed about the nature, significance, and potential benefits of the trial, understands the procedures and methods of the study, is willing to strictly adhere to the clinical trial protocol, and voluntarily signs the informed consent form; 2.The participant is scheduled to undergo elective thoracoscopic lung surgery; 3.The participant is between 18 and 75 years of age, regardless of gender; 4.The participant has an American Society of Anesthesiologists (ASA) physical status classification of I to III; 5.The participant has normal coagulation function test results; 6.The participant's BMI is between 18 and 30 kg/m²;
Exclusion criteria
Exclusion criteria: 1.Patients with liver, kidney, or pulmonary insufficiency, or heart failure of class III or IV; 2.Patients with neurological deficits, sensory disorders such as hyperalgesia, or other physical pain that may interfere with postoperative pain assessment; 3.Patients with a history of myocardial infarction or unstable angina within the past six months, or a history of severe arrhythmias (e.g., second-degree or third-degree atrioventricular block); 4.Patients known to be allergic or contraindicated to bupivacaine or other amide-type local anesthetics; 5.Patients with infection at the injection site or other contraindications for nerve blockade; 6.Pregnant or breastfeeding women, or women planning to conceive within six months, or those unwilling or unable to use effective contraception; 7.Patients with a history of psychiatric disorders or central nervous system diseases, or hearing or visual impairments that prevent cooperation with assessment scales; 8.Patients with diabetic peripheral neuropathy; 9.Patients whom the investigator considers to have any other factors that make them unsuitable for participation in this trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The NRS pain scores at rest and during movement (or coughing) will be recorded at postoperative 1h, 6h, 12h, 24h, and 48h.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Onset time of block (the time from the completion of local anesthetic injection to the reduction of cold sensation on the blocked side of the skin);Total postoperative opioid consumption;The proportion and frequency of patients with postoperative NRS scores >=4;The time of first use of supplemental analgesic medication via PCIA;The proportion of patients who received supplemental analgesic medication within 48 hours postoperatively;QoR-15 score at 48 hours postoperatively;Pain relief satisfaction score;The occurrence of anesthesia-related adverse events; | — |
Countries
China
Contacts
Public ContactXiangyu Fang
Quzhou People Hospital
Outcome results
None listed